BioSig Technologies(BSGM) Newsfilter·2024-07-31 13:45Acquisition Intent - BioSig Technologies has executed a non-binding letter of intent to acquire the assets of Neuro-Kinesis Corporation (NKC), with the purchase price to be paid through the issuance of BioSig's common stock [1][8] - NKC will provide BioSig with a minimum of $2.5 million and potentially up to $6 million in unrestricted cash at closing [1] Management and Expertise - NKC is managed by a team of seasoned professionals with extensive backgrounds in medical technology, electrophysiology, clinical research, regulatory affairs, and technology commercialization [3] - The management team includes notable figures such as Josh Shachar, the CEO, and Dr. Eli Gang, the Chief Medical Officer, who bring significant expertise in their respective fields [24][25] Technology Overview - NKC's Huygens™ Catheter aims to improve the resolution of signal detection in electrophysiology (EP) procedures, addressing limitations of current mapping technologies [23] - The Proteus™ Robotic Arm enhances catheter navigation, providing precision control during EP diagnostic procedures [16][30] - The Huygens™ Catheter incorporates micro-electronics for signal amplification and digital processing, reducing noise contamination and improving signal clarity [28] Market Potential - The acquisition is expected to accelerate the market entry of NKC's breakthrough technology for diagnosing and treating complex cardiac arrhythmias [9] - NKC's technology is positioned to address the needs of the 35% of patients suffering from complex arrhythmias, where traditional ablation therapies are often ineffective [14][23] Future Developments - NKC plans to develop automated EP mapping systems utilizing AI-based applications to enhance the efficiency and efficacy of EP procedures [32] - The company holds an extensive portfolio of 47 issued patents related to its catheter and robotic arm technologies, along with nearly 200 additional patents in the smart surgical device arena [31]